The National Alliance on Mental Illness (NAMI) until recently was reluctant to reveal the source of its funding. But thanks to Sen. Grassley we now can learn NAMI's sources for Major Foundation and Corporate Support, which you can find here.
I downloaded the list of "funders" for 2009. Fortunately, unlike pharmaceutical companies who have revealed monies paid to physicians (see, for example, "Transparency Vs. Translucency in Reporting Physician Payments"), NAMI's numbers are easy to copy into Excel spreadsheets and analyze.
In 2009, NAMI received 84 payments over $5,000 from different sources. Payments total $4,737,610.00 of which $3,836,750.00 (81%) came from major pharmaceutical companies. The following pie chart shows how the $3,836,750.00 was divided among major pharma funders (click on the chart for an enlarged view).
HHS press release here). I guess you might say AZ got a large NEGATIVE ROI for its NAMI investment!
Lilly was next on the list having donated $750,500.00 to NAMI in 2009. Recall that Lilly markets Cymbalta and that it recently received a warning letter from the FDA about misleading a Cymablta print ad -- ie, re: "omission of risk information." Cymbalta is indicated for treatment of depression among many other things these days (see "The Cymbalta Buzz Machine is at Full Throttle!").
The third biggest NAMI pharma "funder" for 2009 was BMS, which donated $506,250.00. Recall that BMS markets the drug Abilify for bipolar disorder. Some time ago, Andy Behrman -- BMS's patient spokesperson for Abilify -- went on a campaign against the very product he endorsed for money (see "Andy Behrman, Now an Anti-BMS Spokesperson, Says 'Ask Your Doctor If Abilify is Wrong for You'").
It's a crazy, crazy world out there in the marketing of mental illness drugs!